Although dialysis patients are known to have impaired antibody responses to pathogens and fluctuation of antibody levels,1 the response to coronavirus disease 2019 (COVID-19) in this population remains to be determined. De Vriese and Reynders2 present the first evaluation of potential antibody responses in a dialysis population. We agree that 2 sequential negative COVID-19 swabs before de-isolating dialysis patients is a reasonable approach, as we recently demonstrated.3 De Vriese and Reynders studied the presence of immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein in 7 patients and concluded that patients develop an antibody response within 15 days.